Mechanisms of progression of chronic kidney disease

Pediatric Nephrology

Volumn 22, Issue 12, 2007, Pages 2011-2022

  Fogo, Agnes B ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angiotensin; Angiotensin I converting enzyme inhibitors (ACEI); Angiotensin receptor blockers; Angiotensin receptors; Glomerulosclerosis; Interstitial fibrosis; Low birth weight; Podocytes; Transforming growth factor (TGF) beta

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLASMINOGEN ACTIVATOR INHIBITOR 1; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY;

CHILD HEALTH; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DNA POLYMORPHISM; DRUG ANTAGONISM; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DYSLIPIDEMIA; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC RISK; GLOMERULOSCLEROSIS; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FIBROSIS; LOW DRUG DOSE; MONOTHERAPY; NEPHRON; NEPHROTIC SYNDROME; NONHUMAN; PATHOGENESIS; PODOCYTE; PRIORITY JOURNAL; PROTEIN RESTRICTION; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; TONSILLECTOMY; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; CHILD; CHRONIC DISEASE; DISEASE PROGRESSION; DYSLIPIDEMIAS; FEMALE; FIBROSIS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION, RENAL; KIDNEY DISEASES; MALE; PODOCYTES; POLYMORPHISM, GENETIC; PROTEINURIA; RENIN-ANGIOTENSIN SYSTEM; TRANSFORMING GROWTH FACTOR BETA;

EID: 36148955109     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-007-0524-0     Document Type: Review

References (135)

1. Foreman JW, Chan JC (1988) Chronic renal failure in infants and children. J Pediatr 113:793-800
2. Drummond K, Mauer M, International Diabetic Nephropathy Study Group (2002) The early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes in type 1 diabetes. Diabetes 51:1580-1587
3. Olson JL, Heptinstall RH (1988) Nonimmunologic mechanisms of glomerular injury. Lab Invest 59:564-578
4. Morrison AB, Howard RM (1966) The functional capacity of hypertrophied nephrons: Effect of partial nephrectomy on the clearance of inulin and PAH in the rat. J Exp Med 123:829-844
5. Shimamura T, Morrison AB (1975). A progressive glomerulosclerosis occurring in partial five-sixths nephrectomized rats. Am J Pathol 79:95-106
6. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM (1981) Hyperfiltration in remnant nephrons: A potentially adverse response to renal ablation. Am J Physiol 241:F85-F93
7. Grond J, Weening JJ, Elema JD (1984) Glomerular sclerosis in nephrotic rats. Comparison of the long-term effects of adriamycin and aminonucleoside. Lab Invest 51:277-285
8. Brenner BM, Meyer TW, Hostetter TH (1982) Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307:652-659
9. Nath KA, Kren SM, Hostetter TH (1986) Dietary protein restriction in established renal injury in the rat. Selective role of glomerular capillary pressure in progressive glomerular dysfunction. J Clin Invest 78:1199-1205
10. Fogo AB (2000) Glomerular hypertension, abnormal glomerular growth, and progression of renal diseases. Kidney Int Suppl 75:S15-21
11. Kakinuma Y, Kawamura T, Bills T, Yoshioka T, Ichikawa I, Fogo A (1992) Blood-pressure independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int 42:46-55
12. Kon V, Fogo A, Ichikawa I (1993) Bradykinin causes selective efferent arteriolar dilatation during angiotensin I converting enzyme inhibition. Kidney Int 44:545-550
13. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 330:1456-1462
14. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF (1993) The effect of blood pressure treatment on the kidney in diabetes: A meta-regression analysis. Ann Intern Med 118:129-138
15. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P (1996) Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334:939-945
16. MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD (2006) Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: A systematic review of the efficacy and safety data. Am J Kidney Dis 48:8-12
17. Yamada T, Horiuchi T, Dzau VJ (1996) Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci USA 93:156-160
18. Stoll M, Steckelings M, Paul M, Bottari SP, Metzger R, Unger T (1995) The angiotensin AT 2 -receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 95:651-657
19. Steckelings UM, Kaschina E, Unger T (2005) The AT2 receptor-a matter of love and hate. Peptides 26:1401-1409
20. Siragy HM (2000) AT(1) and AT(2) receptors in the kidney: Role in disease and treatment. Am J Kidney Dis 36 [3 Suppl 1]:S4-9
21. Ma J, Nishimura H, Fogo A, Kon V, Inagami T, Ichikawa I (1998) Accelerated fibrosis and collagen deposition develop in the renal interstitium of angiotensin type 2 receptor null mutant mice during ureteral obstruction. Kidney Int 53:937-944
22. Ohkubo N, Matsubara H, Nozawa Y, Mori Y, Murasawa S, Kijima K, Maruyama K, Masaki H, Tsutumi Y, Shibazaki Y, Iwasaka T, Inada M (1997) Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation 96:3954-3962
23. Wolf G, Ritz E (2005) Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: Pathophysiology and indications. Kidney Int 67:799-812
24. Ots M, Mackenzie HS, Troy JL, Rennke HG, Brenner BM (1998) Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrol 9:224-230
25. Ma L-J, Nakamura S, Aldigier JC, Rossini M, Yang H, Liang X, Nakamura I, Marcantoni C, Fogo AB (2005) Regression of glomerulosclerosis with high dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol 16:966-976
26. Naito T, Ma L, Donnert E, Fogo AB (2005) Angiotensin type 2 receptor antagonist (AT2RA) worsens glomerulosclerosis in the rat remnant kidney model. J Am Soc Nephrol 16:654A
27. Hashimoto N, Maeshima Y, Satoh M, Odawara M, Sugiyama H, Kashihara N, Matsubara H, Yamasaki Y, Makino H (2004) Overexpression of angiotensin type 2 receptor ameliorates glomerular injury in a mouse remnant kidney model. Am J Physiol Renal Physiol 286:F516-F525
28. Russo D, Pisani A, Balletta MM, De Nicola L, Savino FA, Andreucci M, Minutolo R (1999) Additive antiproteinuric effect of converting enzyme inhibtion and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 33:851-856
29. Hebert LA, Falkenhain ME, Nahman NS Jr, Cosio FG, O'Dorisio TM (1999) Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy. Am J Nephrol 19:1-6
30. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME (2000) Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. BMJ 321:1440-1444
31. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T (2003) Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 361:117-124
32. Taal MW, Brenner BM (2002) Combination ACEI and ARB therapy: Additional benefit in renoprotection? Curr Opin Nephrol Hypertens 11:377-381
33. Nishiyama A, Seth DM, Navar LG (2002) Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats. Hypertension 39:129-134
34. Azizi M, Webb R, Nussberger J, Hollenberg NK (2006) Renin inhibition with aliskiren: Where are we now, and where are we going? J Hypertens 24:243-256
35. Orth SR, Weinreich T, Bönisch S, Weih M, Ritz E (1995) Angiotensin II induces hypertrophy and hyperplasia in adult human mesangial cells. Exp Nephrol 3:23-33
36. Wolf G, Neilson EG (1993) Angiotensin II as a renal growth factor. J Am Soc Nephrol 3:1531-1540
37. Ketteler M, Noble NA, Border WA (1995) Transforming growth factor-b and angiotensin II: The missing link from glomerular hyperfiltration to glomerulosclerosis? Annu Rev Physiol 57:279-295
38. Oikawa T, Freeman M, Lo W, Vaughan DE, Fogo A (1997) Modulation of plasminogen activator inhibitor-1 (PAI-1) in vivo: A new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int 51:164-172
39. Nakamura S, Nakamura I, Ma L, Vaughan DE, Fogo AB (2000) Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int 58:251-259
40. Brown NJ (2005) Aldosterone and end-organ damage. Curr Opin Nephrol Hypertens 14:235-241
41. Epstein M (2006) Aldosterone blockade: An emerging strategy for abrogating progressive renal disease. Am J Med 119:912-919
42. Ma J, Weisberg A, Griffin JP, Vaughan DE, Fogo AB, Brown NJ (2006) Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney Int 69:1064-1072
43. Bianchi S, Bigazzi R, Campese VM (2006) Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 70:2116-2123
44. Weinberger MH, Luft FC (2006) Comprehensive suppression of the renin-angiotensin-aldosterone system in chronic kidney disease: Covering all of the bases. Kidney Int 70:2051-2053
45. Nyengaard JR (1993) Number and dimensions of rat glomerular capillaries in normal development and after nephrectomy. Kidney Int 43:1049-1057
46. Marcussen N, Nyengaard JR, Christensen S (1994) Compensatory growth of glomeruli is accomplished by an increased number of glomerular capillaries. Lab Invest 70:868-874
47. Nyengaard JR, Rasch R (1993) The impact of experimental diabetes mellitus in rats on glomerular capillary number and sizes. Diabetologia 36:189-194
48. Akaoka K, White RHR, Raafat F (1995) Glomerular morphometry in childhood reflux nephropathy, emphasizing the capillary changes. Kidney Int 47:1108-1114
49. Adamczak M, Gross ML, Krtil J, Koch A, Tyralla K, Amann K, Ritz E (2003) Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol 14:2833-2842
50. Adamczak M, Gross ML, Amann K, Ritz E (2004) Reversal of glomerular lesions involves coordinated restructuring of glomerular microvasculature. J Am Soc Nephrol 15:3063-3072
51. Aldigier JC, Kanjanabuch T, Ma L-J, Brown NJ, Fogo AB (2005) Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol 16:3306-3314
52. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M (1998) Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339:69-75
53. Hotta O, Furuta T, Chiba S, Tomioka S, Taguma Y (2002) Regression of IgA nephropathy: A repeat biopsy study. Am J Kidney Dis 39:493-502
54. Fine LG, Hammerman MR, Abboud HE (1992) Evolving role of growth factors in the renal response to acute and chronic disease. J Am Soc Nephrol 2:1163-1170
55. Kashgarian M, Sterzel RB (1992) The pathobiology of the mesangium. Kidney Int 41:524-529
56. Yang HC, Ma LJ, Ma J, Fogo AB (2006) Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis. Kidney Int 69:1756-1764
57. Schmid H, Henger A, Kretzler M (2006) Molecular approaches to chronic kidney disease. Curr Opin Nephrol Hypertens 15:123-129
58. Xu BJ, Shyr Y, Liang X, Ma LJ, Donnert EM, Roberts JD, Zhang X, Kon V, Brown NJ, Caprioli RM, Fogo AB (2005) Proteomic patterns and prediction of glomerulosclerosis and its mechanisms. J Am Soc Nephrol 16:2967-2975
59. Eddy AA, Fogo AB (2006) Plasminogen activator inhibitor-1 in chronic kidney disease: Evidence and mechanisms of action. J Am Soc Nephrol 17:2999-3012
60. Brown NJ, Kim KS, Chen YQ, Blevins LS, Nadeau JH, Meranze SG, Vaughan DE (2000) Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 expression. J Clin Endocrinol Metab 85:336-344
61. Ma LJ, Yang H, Gaspert A, Carlesso G, Barty MM, Davidson JM, Sheppard D, Fogo AB (2003) Transforming growth factor-beta-dependent and -independent pathways of induction of tubulointerstitial fibrosis in beta6(-/-) mice. Am J Pathol 163:1261-1273
62. Gaedeke J, Peters H, Noble NA, Border WA (2001) Angiotensin II, TGF-beta and renal fibrosis. Contrib Nephrol 135:153-160
63. Kopp JB, Factor VM, Mozes M, Nagy P, Sanderson N, Bottinger EP, Klotman PE, Thorgeirsson SS (1996) Transgenic mice with increased levels of TGF-β1 develop progressive renal disease. Lab Invest 74:991-1003
64. Johnson RJ, Raines EW, Floege J, Yoshimura A, Pritzl P, Alpers C, Ross R (1992) Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor. J Exp Med 175:1413-1416
65. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E (1990) Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 346:371-374
66. Christ M, McCartney-Francis NL, Kulkarni AB, Ward JM, Mizel DE, Mackall CL, Gress RE, Hines KL, Tian H, Karlsson S, Wahl SM (1994) Immune dysregulation in TGF-beta 1-deficient mice. J Immunol 153:1936-1946
67. Ma L-J, Sharda J, Hong Ling H, Pozzi A, Ledbetter S, Fogo AB (2004) Divergent effects of low vs high dose anti-TGF-β antibody in puromycin aminonucleoside nephropathy in rats. Kidney Int 65:106-115
68. Sam R, Wanna L, Gudehithlu KP, Garber SL, Dunea G, Arruda JA, Singh AK (2006) Glomerular epithelial cells transform to myofibroblasts: Early but not late removal of TGF-beta1 reverses transformation. Transl Res 148:142-148
69. Schiffer M, Bitzer M, Roberts IS, Kopp JB, ten Dijke P, Mundel P, Bottinger EP (2001) Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest 108:807-816
70. Wu DT, Bitzer M, Ju W, Mundel P, Bottinger EP (2005) TGF-beta concentration specifies differential signaling profiles of growth arrest/ differentiation and apoptosis in podocytes. J Am Soc Nephrol 16:3211-3221
71. Guan Y, Breyer MD (2001) Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease. Kidney Int 60:14-30
72. Buckingham RE, Al-Barazanji KA Toseland CD, Slaughter M, Connor SC, West A, Bond B, Turner NC, Clapham JC (1998) Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 47:1326-1334
73. Ma LJ, Marcantoni C, Linton MF, Fazio S, Fogo AB (2001) Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int 59:1899-1910
74. Shankland SJ (2006) The podocyte's response to injury: Role in proteinuria and glomerulosclerosis. Kidney Int 69:2131-2147
75. Wharram BL, Goyal M, Wiggins JE, Sanden SK, Hussain S, Filipiak WE, Saunders TL, Dysko RC, Kohno K, Holzman LB, Wiggins RC (2005) Podocyte depletion causes glomerulosclerosis: Diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 16:2941-2952
76. Matsusaka T, Xin J, Niwa S, Kobayashi K, Akatsuka A, Hashizume H, Wang QC, Pastan I, Fogo AB, Ichikawa I (2005) Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury. J Am Soc Nephrol 16:1013-1023
77. Ichikawa I, Ma J, Motojima M, Matsusaka T (2005) Podocyte damage damages podocytes: Autonomous vicious cycle that drives local spread of glomerular sclerosis. Curr Opin Nephrol Hypertens 14:205-210
78. Combs HL, Shankland SJ, Setzer SV, Hudkins KL, Alpers CE (1998) Expression of the cyclin kinase inhibitor, p27kip1, in developing and mature human kidney. Kidney Int 53:892-896
79. Shankland SJ (1999) Cell cycle regulatory proteins in glomerular disease. Kidney Int 56:1208-1215
80. Kriz W, Gretz N, Lemley KV (1998) Progression of glomerular diseases: Is the podocyte the culprit? Kidney Int 54:687-697
81. Megyesi J, Price PM, Tamayo E, Safirstein RL (1999) The lack of a functional p21(WAF1/CIP1) gene ameliorates progression to chronic renal failure. Proc Natl Acad Sci USA 96:10830-10835
82. Eremina V, Quaggin SE (2004) The role of VEGF-A in glomerular development and function. Curr Opin Nephrol Hypertens 13:9-15
83. Ruotsalainen V, Ljungberg P, Wartiovaara J, Lenkkeri U, Kestila M, Jalanko H, Holmberg C, Tryggvason K (1999) Nephrin is specifically located at the slit diaphragm of glomerular podocytes. Proc Natl Acad Sci USA 96:7962-7967
84. Huber TB, Benzing T (2005) The slit diaphragm: A signaling platform to regulate podocyte function. Curr Opin Nephrol Hypertens 14:211-216
85. Shih NY, Li J, Karpitskii V, Nguyen A, Dustin ML, Kanagawa O, Miner JH, Shaw AS (1999) Congenital nephrotic syndrome in mice lacking CD2-associated protein. Science 286:312-315
86. Kaplan JM, Kim SH, North KN, Rennke H, Correia LA, Tong HQ, Mathis BJ, Rodriguez-Perez JC, Allen PG, Beggs AH, Pollak MR (2000) Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet 24:251-256
87. Winn MP, Daskalakis N, Spurney RF, Middleton JP (2006) Unexpected role of TRPC6 channel in familial nephrotic syndrome: Does it have clinical implications? J Am Soc Nephrol 17:378-387
88. Boute N, Gribouval O, Roselli S, Benessy F, Lee H, Fuchshuber A, Dahan K, Gubler MC, Niaudet P, Antignac C (2000) NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 24:349-354
89. Karle SM, Uetz B, Ronner V, Glaeser L, Hildebrandt F, Fuchshuber A (2002) Novel mutations in NPHS2 detected in both familial and sporadic steroid-resistant nephrotic syndrome. J Am Soc Nephrol 13:388-393
90. Ruf RG, Lichtenberger A, Karle SM, Haas JP, Anacleto FE, Schultheiss M, Zalewski I, Imm A, Ruf EM, Mucha B, Bagga A, Neuhaus T, Fuchshuber A, Bakkaloglu A, Hildebrandt F, Arbeitsgemeinschaft Für Padiatrische Nephrologie Study Group (2004) Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 15:722-732
91. Hinkes B, Wiggins RC, Gbadegesin R, Vlangos CN, Seelow D, Nurnberg G, Garg P, Verma R, Chaib H, Hoskins BE, Ashraf S, Becker C, Hennies HC, Goyal M, Wharram BL, Schachter AD, Mudumana S, Drummond I, Kerjaschki D, Waldherr R, Dietrich A, Ozaltin F, Bakkaloglu A, Cleper R, Basel-Vanagaite L, Pohl M, Griebel M, Tsygin AN, Soylu A, Muller D, Sorli CS, Bunney TD, Katan M, Liu J, Attanasio M, O'toole JF, Hasselbacher K, Mucha B, Otto EA, Airik R, Kispert A, Kelley GG, Smrcka AV, Gudermann T, Holzman LB, Nurnberg P, Hildebrandt F (2006) Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. Nat Genet 38:1397-1405
92. Mucha B, Ozaltin F, Hinkes BG, Hasselbacher K, Ruf RG, Schultheiss M, Hangan D, Hoskins BE, Everding AS, Bogdanovic R, Seeman T, Hoppe B, Hildebrandt F, Members of the APN Study Group (2006) Mutations in the Wilms' tumor 1 gene cause isolated steroid resistant nephrotic syndrome and occur in exons 8 and 9. Pediatr Res 59:325-331
93. Gbadegesin R, Hinkes B, Vlangos C, Mucha B, Liu J, Hopcian J, Hildebrandt F (2007) Mutational analysis of NPHS2 and WT1 in frequently relapsing and steroid-dependent nephrotic syndrome. Pediatr Nephrol 22:509-513
94. Kawachi H, Koike H, Kurihara H, Yaoita E, Orikasa M, Shia MA, Sakai T, Yamamoto T, Salant DJ, Shimizu F (2000) Cloning of rat nephrin: expression in developing glomeruli and in proteinuric states. Kidney Int 57:1949-1961
95. Forbes JM, Bonnet F, Russo LM, Burns WC, Cao Z, Candido R, Kawachi H, Allen TJ, Cooper ME, Jerums G, Osicka TM (2002) Modulation of nephrin in the diabetic kidney: Association with systemic hypertension and increasing albuminuria. J Hypertens 20:985-992
96. Moller CC, Wei C, Altintas MM, Li J, Greka A, Ohse T, Pippin JW, Rastaldi MP, Wawersik S, Schiavi S, Henger A, Kretzler M, Shankland SJ, Reiser J (2007) Induction of TRPC6 channel in acquired forms of proteinuric kidney disease. J Am Soc Nephrol 18:29-36
97. Benigni A, Tomasoni S, Gagliardini E, Zoja C, Grunkemeyer JA, Kalluri R, Remuzzi G (2001) Blocking angiotensin II synthesis/activity preserves glomerular nephrin in rats with severe nephrosis. J Am Soc Nephrol 12:941-948
98. Cases A, Coll E (2005) Dyslipidemia and the progression of renal disease in chronic renal failure patients. Kidney Int Suppl 99:S87-93
99. Keane WF, Mulcahy WS, Kasiske BL, Kim Y, O'Donnell MP (1991) Hyperlipidemia and progressive renal disease. Kidney Int 39 [Suppl 31]:S41-S48
100. Oda H, Keane WF (1999) Recent advances in statins and the kidney. Kidney Int Suppl 71:S2-S5
101. Fried LF, Orchard TJ, Kasiske BL (2001) Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int 59:260-269
102. Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC; Cholesterol and Recurrent Events Trial Investigators (2003) Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 14:1605-1613
103. Remuzzi G, Bertani T (1990) Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 38:384-394
104. Ruggenenti P, Remuzzi G (2006) Time to abandon microalbuminuria? Kidney Int 70:1214-1222
105. Wolf G, Schroeder R, Ziyadeh FN, Stahl RA (2004) Albumin up-regulates the type II transforming growth factor-beta receptor in cultured proximal tubular cells. Kidney Int 66:1849-1858
106. Perico N, Codreanu I, Schieppati A, Remuzzi G (2005) Pathophysiology of disease progression in proteinuric nephropathies. Kidney Int Suppl 94:S79-S82
107. Abbate M, Zoja C, Remuzzi G (2006) How does proteinuria cause progressive renal damage? J Am Soc Nephrol 17:2974-2984
108. Kang DH, Kanellis J, Hugo C, Truong L, Anderson S, Kerjaschki D, Schreiner GF, Johnson RJ (2002) Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol 13:806-816
109. Kipari T, Hughes J (2002) Macrophage-mediated renal cell death. Kidney Int 61:760-761
110. Ishidoya S, Morrissey J, McCracken R, Reyes A, Klahr S (1995) Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int 47:1285-1294
111. Nishida M, Fujinaka H, Matsusaka T, Price J, Kon V, Fogo AB, Davidson JM, Linton MF, Fazio S, Homma T, Yoshida H, Ichikawa I (2002) Absence of angiotensin II type 1 receptor in bone marrow-derived cells is detrimental in the evolution of renal fibrosis. J Clin Invest 110:1859-1868
112. Katz A, Caramori ML, Sisson-Ross S, Groppoli T, Basgen JM, Mauer M (2002) An increase in the cell component of the cortical interstitium antedates interstitial fibrosis in type 1 diabetic patients. Kidney Int 61:2058-2066
113. Al-Awqati Q, Oliver JA (2002) Stem cells in the kidney. Kidney Int 61:387-395
114. Neilson EG (2006) Mechanisms of disease: Fibroblasts - a new look at an old problem. Nat Clin Pract Nephrol 2:101-108
115. Fogo AB (2003) Hypertensive risk factors in kidney disease in African Americans. Kidney Int 63 Suppl 83:S17-S21
116. Andreoli SP (2004) Racial and ethnic differences in the incidence and progression of focal segmental glomerulosclerosis in children. Adv Ren Replace Ther 11:105-109
117. Barker DJ, Osmond C (1986) Infant mortality, childhood nutrition, and ischaemic heart disease in England and Wales. Lancet 1:1077-1081
118. Brenner BM, Garcia DL, Anderson S (1988) Glomeruli and blood pressure. Less of one, more the other? Am J Hypertens 1:335-347
119. Kleinman JC, Kessel SS (1987) Racial differences in low birth weight. Trends and risk factors. N Engl J Med 317:749-753
120. Pesce C, Schmidt K, Fogo A, Okoye MI, Kim R, Striker LJ, Striker GE (1994) Glomerular size and the incidence of renal disease in African Americans and Caucasians. J Nephrol 7:355-358
121. Hoy WE, Hughson MD, Singh GR, Douglas-Denton R, Bertram JF (2006) Reduced nephron number and glomerulomegaly in Australian Aborigines: A group at high risk for renal disease and hypertension. Kidney Int 70:104-110
122. Douglas-Denton RN, McNamara BJ, Hoy WE, Hughson MD, Bertram JF (2006) Does nephron number matter in the development of kidney disease? Ethn Dis 16 [2 Suppl 2]:S240-S245
123. Austin HA, Boumpas DT, Vaughan EM, Balow JE (1995) High-risk features of lupus nephritis: Importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant 10:1620-1628
124. Casanova S, Mazzucco G, Barbiano di Belgiojoso G, Motta M, Boldorini R, Genderini A, Monga G (1995) Pattern of glomerular involvement in human immunodeficiency virus-infected patients: An Italian study. Am J Kidney Dis 26:446-453
125. Wang Y, Wang YP, Tay YC, Harris DC (2000) Progressive adriamycin nephropathy in mice: Sequence of histologic and immunohistochemical events. Kidney Int 58:1797-1804
126. Ma LJ, Fogo AB (2003) Model of robust induction of glomerulosclerosis in mice: Importance of genetic background. Kidney Int 64:350-355
127. Qi Z, Fujita H, Jin J, Davis LS, Wang Y, Fogo AB, Breyer MD (2005) Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes 54:2628-2637
128. Yoshida H, Kuriyama S, Atsumi Y, Tomonari H, Mitarai T, Hamaguchi A, Kubo H, Kawaguchi Y, Kon V, Matsuoka K, Ichikawa I, Sakai O (1996) Angiotensin-I converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus: Risk for progression to chronic renal failure and mortality. Kidney Int 50:657-664
129. Marre M, Jeunemaitre X, Gallois Y, Rodier M, Chatellier G, Sert C, Dusselier L, Kahal Z, Chaillous L, Halimi S, Muller A, Sackmann H, Bauduceau B, Bled F, Passa P, Alhenc-Gelas F (1997) Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes. J Clin Invest 99:1585-1595
130. Brock JW 3rd, Hunley TE, Adams MC, Kon V (1998) Role of the renin-angiotensin system in disorders of the urinary tract. J Urol 160:1812-819
131. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S, Tiret L, Amoyel P, Alhenc-Gelas F, Soubrier F (1992) Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 359:641-644
132. Yoshida H, Kon V, Ichikawa I (1996) Polymorphisms of the renin-angiotensin system genes in progressive renal diseases. Kidney Int 50:732-744
133. Boonstra A, de Zeeuw D, de Jong PE, Navis G (2001) Role of genetic variability in the renin-angiotensin system in diabetic and nondiabetic renal disease. Semin Nephrol 21:580-592
134. Hunley TE, Julian BA, Phillips JA 3rd, Summar ML, Yoshida H, Horn RG, Brown NJ, Fogo A, Ichikawa I, Kon V (1996) Angiotensin converting enzyme gene polymorphism: potential silencer motif and impact on progression in IgA nephropathy. Kidney Int 49:571-577
135. August P, Leventhal B, Suthanthiran M (2000) Hypertension-induced organ damage in African Americans: transforming growth factor-beta(1) excess as a mechanism for increased prevalence. Curr Hypertens Rep 2:184-191